Profile data is unavailable for this security.
About the company
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s products include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery and acute therapies. Its renal care offering includes peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. Its medication delivery offerings include intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. Its pharmaceuticals offerings include premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. Its clinical nutrition offerings include parenteral nutrition (PN) therapies and related products. Its advanced surgery offerings include biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. It also offers polysaccharide hemostatic system (PerClot) products.
- Revenue in USD (TTM)12.20bn
- Net income in USD1.12bn
- Incorporated1931
- Employees50.00k
- LocationBaxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
- Phone+1 (847) 948-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.baxter.com/
Mergers & acquisitions
| Acquired company | BAX:NYQ since announced | Transaction value |
|---|---|---|
| Hill-Rom Holdings Inc | -9.32% | -- |
| Omnicell Inc | -4.26% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hologic, Inc. | 5.66bn | 2.04bn | 19.41bn | 5.81k | 9.82 | 5.00 | 8.03 | 3.43 | 7.80 | 7.80 | 21.69 | 15.31 | 0.7357 | 3.85 | 6.78 | 973,959.40 | 26.43 | 4.23 | 32.35 | 5.13 | 68.87 | 54.66 | 35.93 | 9.48 | 1.31 | 31.72 | 0.4476 | 0.00 | 12.15 | 6.90 | 661.53 | 53.33 | 11.84 | -- |
| Cooper Companies Inc | 2.66bn | 2.36bn | 20.40bn | 12.00k | 8.74 | 3.31 | 7.68 | 7.67 | 47.39 | 47.39 | 53.63 | 125.26 | 0.3427 | 1.63 | 6.19 | 221,650.00 | 30.34 | 6.23 | 34.87 | 7.11 | 64.76 | 63.66 | 88.54 | 14.52 | 0.746 | 38.19 | 0.2199 | 0.8652 | -8.39 | 6.23 | -48.28 | 3.21 | 5.02 | 0.00 |
| Zimmer Biomet Holdings Inc | 7.89bn | 935.00m | 30.90bn | 20.00k | 33.12 | 2.46 | 15.47 | 3.92 | 4.48 | 4.39 | 37.70 | 60.27 | 0.3296 | 0.9205 | 6.35 | 394,445.00 | 3.92 | 1.15 | 4.39 | 1.29 | 70.66 | 70.65 | 11.90 | 3.82 | 0.9643 | 6.30 | 0.3843 | 66.54 | -12.00 | 3.21 | -112.27 | -- | -1.16 | 1.76 |
| West Pharmaceutical Services Inc. | 2.52bn | 519.20m | 31.67bn | 9.20k | 62.57 | 15.59 | 51.84 | 12.56 | 6.84 | 6.84 | 33.22 | 27.47 | 0.9473 | 4.93 | 6.14 | 274,184.80 | 18.63 | 11.01 | 22.16 | 13.01 | 39.35 | 33.28 | 19.67 | 12.68 | 2.39 | 72.83 | 0.1111 | 18.33 | 16.69 | 8.93 | 43.24 | 29.35 | 5.79 | 7.63 |
| Baxter International Inc | 12.20bn | 1.12bn | 37.57bn | 50.00k | 34.46 | 4.42 | 18.86 | 3.08 | 2.18 | 2.18 | 23.74 | 16.99 | 0.6231 | 3.71 | 6.25 | 243,940.00 | 5.78 | 10.83 | 6.89 | 13.31 | 39.57 | 41.88 | 9.27 | 17.19 | 1.78 | 12.87 | 0.4195 | 20.45 | 2.74 | 3.21 | 36.56 | 22.90 | -4.89 | -5.54 |
| ResMed Inc. | 3.09bn | 457.24m | 39.75bn | 7.77k | 87.44 | 14.67 | 64.56 | 12.86 | 3.12 | 3.12 | 21.17 | 18.62 | 0.6796 | 3.07 | 5.62 | 397,820.60 | 10.05 | 12.62 | 11.93 | 14.75 | 58.16 | 57.71 | 14.79 | 18.46 | 1.12 | 20.72 | 0.2125 | 45.44 | 13.44 | 11.99 | 51.41 | 11.99 | 8.05 | 6.85 |
| DexCom, Inc. | 2.17bn | 530.60m | 49.78bn | 5.50k | 96.36 | 24.91 | 81.10 | 22.94 | 5.34 | 5.34 | 21.82 | 20.66 | 0.5407 | 2.69 | 5.56 | 394,527.30 | 13.22 | 5.78 | 15.11 | 6.78 | 69.96 | 66.09 | 24.45 | 7.98 | 5.25 | 4.02 | 0.4695 | 0.00 | 30.54 | 36.81 | 388.23 | -- | 42.98 | -- |
| Align Technology, Inc. | 3.47bn | 698.45m | 56.03bn | 18.07k | 80.69 | 16.56 | 97.68 | 16.13 | 8.77 | 8.77 | 43.66 | 42.77 | 0.7375 | 5.77 | 5.42 | 192,265.80 | 14.83 | 29.32 | 20.59 | 42.44 | 74.27 | 73.28 | 20.10 | 33.47 | 1.21 | -- | -- | 0.00 | 2.71 | 23.93 | 301.08 | 65.27 | 23.72 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Mar 2021 | 51.11m | 10.16% |
| The Vanguard Group, Inc.as of 31 Mar 2021 | 36.87m | 7.33% |
| BlackRock Fund Advisorsas of 31 Mar 2021 | 26.64m | 5.30% |
| Morgan Stanley Investment Management Ltd.as of 31 Mar 2021 | 23.49m | 4.67% |
| Generation Investment Management LLPas of 31 Mar 2021 | 20.98m | 4.17% |
| SSgA Funds Management, Inc.as of 31 Mar 2021 | 20.52m | 4.08% |
| Veritas Asset Management LLPas of 31 Mar 2021 | 11.21m | 2.23% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2021 | 9.64m | 1.92% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2021 | 8.98m | 1.79% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Mar 2021 | 7.92m | 1.58% |
